Close

Help us reach $1,000,000! Match My Donation

Immunotherapy for Bladder Cancer
Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link
  • About Immunotherapy
  • CRI's Impact
  • Related News & Resources

What Makes Immunotherapy a Promising Treatment for Bladder Cancer?

Reviewed By: Padmanee Sharma, M.D., Ph.D.
Details
The University of Texas MD Anderson Cancer Center, Houston, TX
Share

One of the most common cancers in the U.S., bladder cancer affects men more likely than women—with an estimated 77,000 new cases predicted to be diagnosed in 2016, and approximately 16,000 deaths expected. Because of the recurrent nature of bladder cancer, patients with bladder cancer must monitor their health closely for an extended period of time.

Immunotherapy has seen and continues to deliver promising results in the treatment of bladder cancer—the first diagnosis for which immunotherapy became avilable, with the approval of the BCG (Bacillus Calmette–Guérin) vaccine in 1990. Since then, five checkpoint inhibitors—atezolizumab, avelumab, durvalumab, nivolumab, and pembrolizumab—have been approved for advanced bladder cancer, and there are numerous additional immune-based treatments for bladder cancer currently in development, with immunotherapy clinical trials for bladder cancer patients on the rise.

Bladder cancer immunotherapy has significantly reduced the risk of recurrence for bladder cancer, while also increasing the percentage of patients who see a complete response post-surgery. Investigational bladder cancer immunotherapies—those that "train" the body's immune system to recognize bladder cancer cells—have the potential to further improve the general outcomes for patients with this disease.

CRI's Impact on Bladder Cancer

Thanks to groundbreaking advancements in immunology research and clinical trials, immunotherapy has become one of the most promising bladder cancer treatments of our time.

Currently, the overall 5-year survival rate for bladder cancer is 77%—a rate which has not changed significantly over the last 10 years. Additionally, no new drugs for bladder cancer were approved by the FDA during this time.

New and developing bladder cancer immunotherapies have the potential to reduce recurrence rates and improve survival rates for patients with bladder cancer. Join us as we work to change the future of bladder cancer treatment—forever.

Featured Story

Most of all, I want the gift of immunotherapy to be accessible to everyone.

Stephen Estrada
Colorectal Cancer  |  Diagnosed 2013
Read My Story
Changing the Future of Cancer Research

As a science-first organization dedicated to supporting cancer immunotherapy research, we're funding a future that fights back against cancer—all with your help.

Support our mission to cure ALL cancers, for good.

Make a Donation

Join Team CRI by supporting our many dedicated fundraisers.

Support the Cause

*Immunotherapy results may vary from patient to patient.

Contact Us

Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111

(800) 992-2623(212) 832-9376Staff Directory

Stay Connected with CRI

Follow us
Top